Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor

Future Virology

Volumn 12, Issue 7, 2017, Pages 339-347

  Elfiky, Abdo A ^a,b   Ismail, Alaa M ^a,c  

^a CAIRO UNIVERSITY   (Egypt)

^b ABDUS SALAM INTERNATIONAL CENTRE FOR THEORETICAL PHYSICS   (Italy)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

direct acting antivirals; HCV NS5b; IDX 184; molecular docking; molecular modeling; nucleoside inhibitor

Indexed keywords

ENZYME INHIBITOR; IDX 184; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; SOFOSBUVIR;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; ENZYME ACTIVE SITE; HEPATITIS C VIRUS; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; QUANTUM MECHANICS;

EID: 85024475880     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl-2017-0027     Document Type: Article

References (43)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359-362 (1989).
2. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 58(1), 1-16 (2003).
3. Yan S, Appleby T, Larson G et al. Structurebased design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg. Med. Chem. Lett. 16(22), 5888-5891 (2006).
4. De Francesco R, Carfí A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv. Rev. 59(12), 1242-1262 (2007).
5. Lemon SM, Mckeating JA, Pietschmann T et al. Development of novel therapies for hepatitis C. Antiviral Res. 86(1), 79-92 (2010).
6. Massariol MJ, Zhao S, Marquis M, Thibeault D, White PW. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. Biochem. Biophys. Res. Commun. 391(1), 692-697 (2010).
7. Das D, Hong J, Chen SH et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorg. Med. Chem. 19(16), 4690-4703 (2011).
8. Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Anti-HCV drugs in the pipeline. Curr. Opin. Virol. 1(6), 607-616 (2011).
9. Firpi RJ, Nelson DR. Current and future hepatitis C therapies. Arch. Med. Res. 38(6), 678-690 (2007).
10. Suzuki T, Ishii K, Aizaki H, Wakita T. Hepatitis C viral life cycle. Adv. Drug. Deliv. Rev. 59(12), 1200-1212 (2007).
11. Delang L, Vliegen I, Leyssen P, Neyts J. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J. Hepatol. 56(1), 41-48 (2012).
12. Chinnaswamy S, Cai H, Kao C. An update on small molecule inhibitors of the HCV NS5B polymerase: effects on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies. Virus Adapt. Treat. 2(1), 73-89 (2010).
13. Doublie S, Ellenberger T. The mechanism of action of T7 DNA polymerase. Curr. Opin. Struct. Biol. 8(6), 704-712 (1998).
14. O'Farrell D, Trowbridge R, Rowlands D, Jäger J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol. 326(4), 1025-1035 (2003).
15. Talele TT, Arora P, Kulkarni SS et al. Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. 18(13), 4630-4638 (2010).
16. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J-M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56 S88-S100 (2012).
17. Beaulieu PL, Gillard J, Jolicoeur E et al. From benzimidazole to indole-5-carboxamide thumb pocket i inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons. Bioorg. Med. Chem. Lett. 21(12), 3658-3663 (2011).
18. Elfiky AA, Elshemey WM, Gawad WA. 2′-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in Hepatitis C virus inhibition: a molecular modeling study. J. Comput. Theor. Nanosci. 12(3), 376-386 (2015).
19. Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bolyai J, Mayers D. Safety and pharmacokinetics of IDX184, a livertargeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob. Agents Chemother. 55(1), 76-81 (2011).
20. Mayhoub AS. Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorg. Med. Chem. 20(10), 3150-3161 (2012).
21. Ibrahim M, Saleh NA, Elshemey WM, Elsayed AA. Hexapeptide functionality of cellulose as NS3 protease inhibitors. Med. Chem. 8(5), 826-830 (2012).
22. Elfiky AA, Elshemey WM, Gawad WA, Desoky OS. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 32(1), 75-80 (2013).
23. Elfiky AA, Elshemey WM. IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study. Med. Chem. Res. 25 1005-1008 (2016).
24. Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J. Med. Virol. 88(12), 2044-2051 (2016).
25. Ibrahim M, Saleh NA, Hameed AJ, Elshemey WM, Elsayed AA. Structural and electronic properties of new fullerene derivatives and their possible application as HIV-1 protease inhibitors. Spectrochim. Acta A. Mol. Biomol. Spectrosc. 75(2), 702-709 (2010).
26. Saleh NA. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors. Spectrochim. Acta A. Mol. Biomol. Spectrosc. 136PC, 1523-1529 (2014).
27. Leach A. Molecular Modelling: Principles and Applications (2nd Edition). Prentice Hall, Nj, USA (2001).
28. Elfiky AA, Gawad WA, Elshemey WM. Hepatitis C Viral polymerase inhibition using directly acting antivirals, a computational approach. Soft. Tech. Bio-Mol. Modeling (13), 197 (2016).
29. Ganesan A, Barakat K. Applications of computer-aided approaches in the development of hepatitis C antiviral agents. Expert Opin. Drug Discov. 12(4), 407-425 (2017).
30. Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J. Med. Virol. 89(6), 1040-1047 (2017).
31. National Center of Biotechnology Informatics (NCBI) database website (2017). http://www.ncbi.nlm.nih.gov/
32. Elshemey WM, Elfiky AA, Gawad WA. Correlation to protein conformation of wide-angle X-ray scatter parameters. Protein. J. 29(8), 545-550 (2010).
33. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 4(3), 363-371 (2009).
34. Structural Analysis and Verification Server website (2017). http://nihserver.mbi.ucla.edu/SAVES/
35. Laskowski RA, Rullmann JaC, Macarthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8(4), 477-486 (1996).
36. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. Nature 381(6580), 272 (1996).
37. Macarthur MW, Laskowski RA, Thornton JM. Knowledge-based validation of protein structure coordinates derived by x-ray crystallography and NMR spectroscopy. Curr. Opin. Struct. Biol. 4(5), 731-737 (1994).
38. Pontius J, Richelle J, Wodak SJ. Deviations from standard atomic volumes as a quality measure for protein crystal structures. J. Mol. Biol. 264(1 ), 121-136 (1996).
39. Murakami E, Tolstykh T, Bao H et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 285(45), 34337-34347 (2010).
40. Lii JH, Allinger NL. Molecular mechanics. The MM3 force field for hydrocarbons.3 The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons. J. Am. Chem. Soc. 111(23), 8576-8582 (1989).
41. Stewart JJP. Optimization of parameters for semiempirical methods. III Extension of PM3 to Be, Mg, Zn, Ga, Ge, As, Se, Cd, In, Sn, Sb, Te, Hg, Tl, Pb, and Bi. J. Comput. Chem. 12(3), 320-341 (1991).
42. Summers KL, Mahrok AK, Dryden MD, Stillman MJ. Structural properties of metal-free apometallothioneins. Biochem. Biophys. Res. Commun. 425(2), 485-492 (2012).
43. Harrus D, Ahmed-El-Sayed N, Simister PC et al. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J. Biol. Chem. 285(43), 32906-32918 (2010).